Watson and colleagues (2005[96]) conducted a study on patients with mild to moderate AD and showed that in patients without ApoE ε4 allele there was improvement in cognition and modulation of Aβ levels in cerebral spinal fluid while patients with ApoE ε4 did not respond to the drug (Rosiglitazone) and showed no improvement. Here, APOE is linked to Alzheimer disease.